XOMA (NASDAQ:XOMA) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of XOMA (NASDAQ:XOMA) in a research report released on Friday morning,Benzinga reports. HC Wainwright currently has a $123.00 price objective on the biotechnology company’s stock.

XOMA Stock Performance

NASDAQ XOMA opened at $27.15 on Friday. The company has a 50-day moving average price of $30.05 and a two-hundred day moving average price of $27.67. XOMA has a 52 week low of $15.56 and a 52 week high of $35.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52.

Insider Buying and Selling at XOMA

In other news, CEO Owen Hughes sold 21,881 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total value of $655,335.95. Following the completion of the sale, the chief executive officer now directly owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. This represents a 38.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 7.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On XOMA

Large investors have recently modified their holdings of the stock. Ellsworth Advisors LLC acquired a new position in XOMA in the 3rd quarter worth approximately $516,000. Price T Rowe Associates Inc. MD acquired a new stake in shares of XOMA in the first quarter worth $212,000. Barclays PLC grew its holdings in shares of XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 8,447 shares in the last quarter. Bank of New York Mellon Corp raised its position in XOMA by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after buying an additional 1,968 shares during the period. Finally, State Street Corp raised its position in XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after buying an additional 1,754 shares during the period. 95.92% of the stock is owned by institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.